Novartis Ag (NVS) Other Non-Current Liabilities (2009 - 2026)

Novartis Ag has reported Other Non-Current Liabilities for 18 years, with the latest figure at $3.9 billion in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 8.18% year-over-year to $3.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.9 billion (down 8.18% YoY) and the FY2025 annual result came in at $4.1 billion, up 1.42% from the prior year.
• Other Non-Current Liabilities grew to $3.9 billion in Q2 2026 per NVS's latest filing, from -$100.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.4 billion in Q2 2022 and troughed at -$100.0 million in Q1 2026.
• A 5-year average of $4.0 billion and a median of $4.3 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities fell 20.51% in 2022, then climbed 1.42% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $4.9 billion in 2022, then decreased by 7.81% to $4.5 billion in 2023, then declined by 9.9% to $4.1 billion in 2024, then climbed by 1.42% to $4.1 billion in 2025, then decreased by 5.76% to $3.9 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.9 billion, -$100.0 million, and $4.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.